At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs) in Combination With Low Dose IL-2 and GM-CSF
In Brief
A Phase 2 clinical trial evaluating Aldesleukin, Antibody Therapy, and 8 other interventions for Metastatic Pancreatic Adenocarcinoma and 3 related conditions. Completed, enrolled 2 participants across 1 site.
Detailed Summary
This phase Ib/II trial studies the side effects and best dose of bispecific antibody armed activated T-cells when given together with aldesleukin and sargramostim and to see how well they work in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Bispecific antibody armed activated T-cells are the patient's own T cells that are coated with a bispecific antibody comprising 2 antibodies chemically joined together. These antibodies have specific targets and binding properties that may give the T cells a greater ability to seek out, attach to, and kill more cancer cells.
Study Details
Timeline
Interventions
Given SC
Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
Given IV
Given IV
Given IV
Correlative studies
Given IV
Given IV
Given IV
Given SC